Nedaplatin vs cisplatin-combined chemotherapy for advanced malignant tumors / 肿瘤研究与临床

ABSTRACT

Objective The efficacies of nedaplatin-combined chemotherapy were compared with those of cisplatin-combined chemotherapy in patients with advanced malignant tumors. Methods Two hundred and sixty-two patients were divided into two groups randomly, the nedaplatin(NDP) group (M94, F36, median age 58y) and the eisplatin(Cis) group (M95, F37, median age 57y). Cycles were repeated every 4 weeks. Effects were assessed after 2 cycles. First-line schedules were chosen, and nedaplatin and cisplatin were used respectively. Results The results showed that the remission rate (50.8 %) in NDP group was significantly higher than that (40.2 %) in Cis group (P<0.05). The NDP had better efficacy than Cis especially in treating ovary cancer and esophageal cancer. The toxicity of NDP was milder for gastro-intestinal tract but more serious for bone marrow than that of Cis(P<0.01). Conclusion As a new broad-spectrum anti-tumor agent, NDP could be a better choice than cisplatin in the treatment of malignant tumors. It is especially of better efficacy in treating ovary cancer and esophageal cancer, and could be recommended as the first-line drugs.